Update on lipid membrane microdomains

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 2, 2008, Pages 106-112

  Schmitz, Gerd ^a   Grandl, Margot ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Disease; Lipid membrane microdomain; Metabolic overload

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A1; CHOLESTEROL; DOCOSAHEXAENOIC ACID; EZETIMIBE; FATTY ACID; NORDIHYDROGUAIARETIC ACID; QUERCETIN; RIFAMPICIN; TANNIN;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CAVEOLA; CELL MIGRATION; CELL POLARITY; CELL SELECTION; CHOLESTEROL DIET; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG TARGETING; HUMAN; LIPID DIET; LIPID MEMBRANE; METABOLIC ACTIVATION; METABOLIC DISORDER; MOLECULAR DYNAMICS; OBESITY; PROTEIN DOMAIN; REVIEW; VIRUS INFECTION;

ANIMALS; CELL MEMBRANE; CHOLESTEROL; DIETARY FATS; GLYCOLIPIDS; HUMANS; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MEMBRANE PROTEINS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 40049084960     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282f44c2c     Document Type: Review

References (60)

1. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84:1341-1379.
2. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110:597-603.
3. Ma DW. Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab 2007; 32:341-350. This review focuses on membrane rafts and their role in human health and disease, and dicusses effects of various lipids, including dietary lipids, on membrane raft structure and function.
4. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 2006; 47:1597-1598.
5. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006; 7:456-462. This article reconsiders the raft hypothesis, delineating the biophysical properties of model membranes and the limitations of the biochemical approaches that have been used to study rafts in biological membranes.
6. Meder D, Moreno MJ, Verkade P, et al. Phase coexistence and connectivity in the apical membrane of polarized epithelial cells. Proc Natl Acad Sci U S A 2006; 103:329-334.
7. Hanzal-Bayer MF, Hancock JF. Lipid rafts and membrane traffic. FEBS Lett 2007; 581:2098-2104.
8. Harder T, Engelhardt KR. Membrane domains in lymphocytes: from lipid rafts to protein scaffolds. Traffic 2004; 5:265-275.
9. Rajendran L, Simons K. Lipid rafts and membrane dynamics. J Cell Sci 2005; 118:1099-1102.
10. Shogomori H, Brown DA. Use of detergents to study membrane rafts: the good, the bad, and the ugly. Biol Chem 2003; 384:1259-1263.
11. Munro S. Lipid rafts: elusive or illusive? Cell 2003; 115:377-388.
12. Edidin M. The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct 2003; 32:257-283.
13. Shaw AS. Lipid rafts: now you see them, now you don't. Nat Immunol 2006; 7:1139-1142. This is a critical view of the lipid raft hypothesis. The difficulties in observing lipid rafts and experimental approaches available for raft investigation are considered.
14. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 2004; 33:269-295.
15. Gaus K, Gratton E, Kable EP, et al. Visualizing lipid structure and raft domains in living cells with two-photon microscopy. Proc Natl Acad Sci U S A 2003; 100:15554-15559.
16. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy. J Cell Sci 2000; 113 (Pt 12):2103-2109.
17. Kurzchalia TV, Parton RG. Membrane microdomains and caveolae. Curr Opin Cell Biol 1999; 11:424-431.
18. Callera GE, Montezano AC, Yogi A, et al. Vascular signaling through cholesterol-rich domains: implications in hypertension. Curr Opin Nephrol Hypertens 2007; 16:90-104. This review focuses on recent advances in signal transduction through caveolae/lipid rafts, which have been implicated in hypertension.
19. Schmitz G, Grandl M. Role of redox regulation and lipid rafts in macrophages during Ox-LDL-mediated foam cell formation. Antioxid Redox Signal 2007; 9:1499-1518. This review describes the importance of lipid rafts in redox regulation and signalling processing in macrophage foam cell formation and atherosclerosis.
20. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 2007; 99: 129-140. This review addresses the importance of lipid raft proteins and lipids in health and disease, with a focus on the current state of knowledge.
21. Inokuchi J. Insulin resistance as a membrane microdomain disorder. Biol Pharm Bull 2006; 29:1532-1537.
22. Fruhbeck G, Lopez M, Dieguez C. Role of caveolins in body weight and insulin resistance regulation. Trends Endocrinol Metab 2007; 18:177-182. The participation of caveolins as novel modulators of adipocyte biology, their role in insulin signalling and their potential relevance to development and treatment of obesity in humans is discussed.
23. Perusse L, Rankinen T, Zuberi A, et al. The human obesity gene map: the 2004 update. Obes Res 2005; 13:381-490.
24. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007; 8:128-140. The role of lipid rafts in neurotransmitter signalling is reviewed. Different trafficking and signalling pathways are taken into account.
25. Cordy JM, Hussain I, Dingwall C, et al. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003; 100:11735-11740.
26. Ehehalt R, Keller P, Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160:113-123.
27. Molander-Melin M, Blennow K, Bogdanovic N, et al. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 2005; 92:171-182.
28. Chen TY, Liu PH, Ruan CT, et al. The intracellular domain of amyloid precursor protein interacts with flotillin-1, a lipid raft protein. Biochem Biophys Res Commun 2006; 342:266-272. Glutathione S-transferase pull-down and co-immunoprecipitation studies revealed that the intracellular domain of APP interacts with flotillin-1. It is proposed that flotillin-1 may recruit APP to lipid rafts and therefore participate in the localization and processing of APP.
29. Kokubo H, Lemere CA, Yamaguchi H. Localization of flotillins in human brain and their accumulation with the progression of Alzheimer's disease pathology. Neurosci Lett 2000; 290:93-96.
30. Girardot N, Allinquant B, Langui D, et al. Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease. Neuropathol Appl Neurobiol 2003; 29:451-461.
31. Rajendran L, Knobloch M, Geiger KD, et al. Increased Abeta production leads to intracellular accumulation of Abeta in flotillin-1-positive endosomes. Neurodegener Dis 2007; 4:164-170. Intracellular β-amyloid peptide accumulates in flotillin-1 positive endocytic vesicles, and flotillin-1 is not only associated with intracellular β-amyloid peptide in transgenic mice but also with extracellular β-amyloid plaques in brain sections from patients with Alzheimer's disease.
32. Hattori C, Asai M, Onishi H, et al. BACE1 interacts with lipid raft proteins. J Neurosci Res 2006; 84:912-917. Caveolin-1 and flotillin-1 may modulate b-secretase activity by interacting with BACE1.
33. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005; 46:949-968.
34. Gulbins E, Dreschers S, Wilker B, Grassme H. Ceramide, membrane rafts and infections. J Mol Med 2004; 82:357-363.
35. Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta 2005; 1746:284-294.
36. Ma DW, Seo J, Switzer KC, et al. n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 2004; 15:700-706.
37. Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of lipid rafts by Omega- 3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract 2007; 22:74-88. This review discusses alteration of lipid rafts by n-3 PUFAs and consequent effects on function of several proteins that are involved in cell signalling, with a focus on inflammation and cancer.
38. Shaikh SR, Edidin M. Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation. Am J Clin Nutr 2006; 84:1277-1289.
39. Shaikh SR, Edidin M. Immunosuppressive effects of polyunsaturated fatty acids on antigen presentation by human leukocyte antigen class I molecules. J Lipid Res 2007; 48:127-138.
40. Ma DW, Seo J, Davidson LA, et al. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J 2004; 18:1040-1042.
41. Bist A, Fielding PE, Fielding CJ. Two sterol regulatory element-like sequences mediate up regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci U S A 1997; 94:10693-10698.
42. Burgermeister E, Tencer L, Liscovitch M. Peroxisome proliferator- activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene 2003; 22:3888-3900.
43. Dobrosotskaya IY, Seegmiller AC, Brown MS, et al. Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila. Science 2002; 296:879-883.
44. Schroeder F, Atshaves BP, McIntosh AL, et al. Sterol carrier protein-2: new roles in regulating lipid rafts and signaling. Biochim Biophys Acta 2007; 1771:700-718. The findings presented here suggest that SCP-2 serves not only in cholesterol and phospholipid transfer, but also in regulating multiple lipid signalling pathways in lipid raft/caveolae microdomains of the plasma membrane.
45. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A 2005; 102:10858-10863.
46. Oksman M, Iivonen H, Hogyes E, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23:563-572.
47. Lukiw WJ. Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. Expert Rev Neurother 2006; 6:683-693.
48. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69:878-885. This study demonstrates an association between antecedent statin use and neurofibrillary tangle burden at autopsy.
49. Hennig B, Reiterer G, Majkova Z, et al. Modification of environmental toxicity by nutrients: implications in atherosclerosis. Cardiovasc Toxicol 2005; 5:153-160.
50. Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols. J Biol Chem 2006; 281:25054-25061. This report provides a biochemical mechanism for the hypocholesterolaemic effects of vitamin E.
51. Taieb N, Yahi N, Fantini J. Rafts and related glycosphingolipid-enriched microdomains in the intestinal epithelium: bacterial targets linked to nutrient absorption. Adv Drug Deliv Rev 2004; 56:779-794.
52. Fantini J. Synthetic soluble analogs of glycolipids for studies of virus-glycolipid interactions. Methods Enzymol 2000; 311:626-638.
53. Mahfoud R, Mylvaganam M, Lingwood CA, Fantini J. A novel soluble analog of the HIV-1 fusion cofactor, globotriaosylceramide (Gb(3)), eliminates the cholesterol requirement for high affinity gp120/Gb(3) interaction. J Lipid Res 2002; 43:1670-1679.
54. Orso E, Werner T, Wolf Z, et al. Ezetimib influences the expression of raft-associated antigens in human monocytes. Cytometry A 2006; 69:206-208.
55. Drobnik W, Borsukova H, Bottcher A, et al. Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains. Traffic 2002; 3:268-278.
56. Gaus K, Kritharides L, Schmitz G, et al. Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages. FASEB J 2004; 18:574-576.
57. Anantharamaiah GM, Mishra VK, Garber DW, et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007; 48:1915-1923.
58. van der Luit AH, Vink SR, Klarenbeek JB, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6:2337-2345. Show that the uptake of alkylphospholipids, which unlike conventional chemotherapeutic drugs act on cell membranes to induce apoptosis in tumour cells, is dependent on lipid rafts.
59. Matsuzaki K, Noguch T, Wakabayashi M, et al. Inhibitors of amyloid beta-protein aggregation mediated by GM1-containing raft-like membranes. Biochim Biophys Acta 2007; 1768:122-130. The authors showed that nordihydroguaiaretic acid, rifampicin, tannic acid and quercetin exhibit potent fibrillization inhibitory activity in the presence of GM1 containing raft-like liposomes.
60. Biro A, Cervenak L, Balogh A, et al. Novel anticholesterol monoclonal immunoglobulin G antibodies as probes and potential modulators of membrane raft-dependent immune functions. J Lipid Res 2007; 48:19-29. The authors produced two monoclonal anticholesterol antibodies by immunizing mice with cholesterol-rich liposomes, which may serve as probes of clustered cholesterol in live cells and thus may also have immunomodulatory potential.